pharmaphorum

SEPTEMBER 23, 2020

Sixfold Bioscience in partnership with Medicines Discovery Catapult, has been given the green light, through the award of an Innovate UK Smart Grant to test a pioneering system designed to deliver drugs directly to cancerous cells, without impacting the healthy cells around it.

Drug Delivery Systems 140

Drug Delivery Systems Gene Silencing Drug Delivery Medicine 140

pharmaphorum

APRIL 28, 2022

Harness Safe & Efficacious Lipid-Based Delivery for Novel Therapeutics Beyond RNA & Hepatic Tissue. The recent success of the mRNA-LNP vaccines fueled biopharma to explore lipid-based nanoparticles for advanced drug delivery.

RNA 52

RNA Drug Delivery Engineer Gene Therapy 52

Drug Discovery World

MARCH 3, 2023

SiSaf is to collaborate with the University of Leipzig, Germany, to develop targeted micro interfering RNAs (miRNA) for the treatment of cancer, with an initial focus on pancreatic cancer. The collaboration will combine SiSaf’s expertise in RNA delivery using its Bio-Courier silicon-stabilised hybrid lipid nanoparticles (sshLNPs) and the University (..)

Development 52

Development RNA Drug Delivery Regulation 52

XTalks

JUNE 14, 2023

XTALKS WEBINAR: Drug Delivery — Evaluating Off-The-Shelf and Novel Drug Delivery Solutions Live and On-Demand: Tuesday, July 11, 2023, at 1pm EDT (10am PDT) Register for this free webinar to learn about important tradeoffs when considering an off-the-shelf (OTS) drug delivery platform vs. novel development.

Gene Silencing 97

Gene Silencing Drug Delivery FDA Approval RNA 97

Drug Discovery World

JUNE 22, 2023

Exosome-based drugs have the potential to address some of the limitations of genetic medicines such as gene therapy, gene editing, and RNA therapeutics by enabling safe non-immunogenic repeated delivery to cells and tissues that are currently out of reach using other drug delivery technologies.

Gene Therapy 52

Gene Therapy Gene Editing Drug Delivery Gene 52

Roots Analysis

MARCH 8, 2023

Over time, various research studies have demonstrated the potential of exosomes ( membrane bound extracellular vesicles) in disease diagnosis, drug delivery and therapeutic applications. In addition, they are involved in regulating the expression of the targets that are linked to RNA as they can affect the expression of RNA.

RNA 52

RNA Drug Delivery DNA Development 52

The Pharma Data

JUNE 7, 2023

Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver. LNPs are spheric drug delivery bodies which can be equipped with therapeutic payloads for intracellular delivery.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

The Pharma Data

OCTOBER 27, 2020

“Applying 3a’s proprietary enhanced RNA technology to PCR testing was a logical next step in our product development pipeline,” said Dr. Heinrich Jehle, managing director of 3a-Diagnostics. “We are currently developing two saliva-based tests to detect SARS-CoV-2 RNA. About XPhyto Therapeutics Corp.

RNA 52

RNA Drug Delivery Production In-Vitro 52

Roots Analysis

FEBRUARY 13, 2023

Further, the biggest challenge in this domain is the purification which involve the use of hazardous solvents / materials and stability of drug products ( thereby, requiring specialized facilities and cold chain transportation).

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

Roots Analysis

MARCH 16, 2023

In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent. Cancer Immunotherapies : RNA molecules, such as siRNA, microRNA, and mRNA, have shown tremendous potential for immunomodulation and use as a cancer immunotherapy.

Vaccination 52

Vaccination Vaccine DNA Protein 52

Drug Discovery World

AUGUST 9, 2023

Darren Mercer, Chief Executive of CSP, said: “We are thrilled to acquire AxeroVision, and in particular the pipeline product AXR-270 which contains a novel selective glucocorticoid receptor agonist formulated in a cutting-edge drug delivery system that overcomes the issues of poor compliance and inefficient delivery of conventional eye drops.”

Drugs 52

Drugs Drug Delivery Systems Drug Delivery Life Science 52

Roots Analysis

OCTOBER 13, 2023

Over the last two decades the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to more enhanced, potent, and targeted therapeutics. This led the researchers to find alternative pathways and drug delivery strategies to enhance the potent delivery of the drug to the site of action.

Drugs 40

Drugs Antibody RNA Genetics 40

XTalks

AUGUST 30, 2022

One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Some methods of direct CNS administration include intrathecal, intraparenchymal and intracerebroventricular (ICV) delivery.

Trials 83

Trials Drug Delivery Drugs Gene 83

Roots Analysis

FEBRUARY 18, 2022

In the 20 th century, major research went into discovery of a therapeutic class with the primary purpose of interfering with the RNA expression linked to disease causing proteins, nowadays classified as oligonucleotides. Our Social Media Platform. Web: [link]. LinkedIn: [link]. Twitter: [link]. Medium: [link]. Pinterest: [link].

Contract Manufacturing 52

Contract Manufacturing Manufacturing Drug Delivery Systems RNA 52

Drug Discovery World

NOVEMBER 30, 2022

The companies hope to meet the demand for a large-scale, high-efficiency purification technology that overcomes critical issues associated with the production of clinical-quality exosomes as delivery vehicles for gene-based therapeutics. .

Production 52

Production Immune Response RNA Gene 52

Drug Discovery World

JANUARY 17, 2023

Oregon State University College of Pharmacy scientists have shown that lipid nanoparticles and messenger RNA could treat blindness associated with a rare genetic condition. . Researchers developed nanoparticles able to penetrate the neural retina and deliver mRNA to the photoreceptor cells whose proper function makes vision possible. .

Gene Editing 98

Gene Editing Gene Gene Therapy Genetics 98

Drug Discovery World

AUGUST 3, 2022

Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake. This method is generally used to deliver small interfering RNA (siRNA), but it can also be used for larger oligonucleotides too.

Bioavailability 52

Bioavailability In-Vivo RNA In-Vitro 52

Delveinsight

FEBRUARY 25, 2021

Beam adds to drug delivery stable with USD 120 Million GuideTx buy. The GuideTx technology screens for lipid nanoparticles inside the body that can be used to deliver RNA to cells throughout the body. Beam announced that it paid USD 120 million upfront to acquire Guide Therapeutics in an all-stock agreement.

DNA 52

DNA In-Vivo Genetics Medicine 52

The Pharma Data

JANUARY 17, 2021

“This marks another significant milestone as we continue to leverage our polypeptide nano-particle technology for siRNA drug delivery to advance our pipeline of oncology therapeutic candidates,” said Patrick Lu , Ph.D., the founder, President and CEO of Sirnaomics. Chief Medical Officer. 1 and COX-2 gene expression.

Gene Expression 52

Gene Expression Trials Production Development 52

Roots Analysis

JANUARY 3, 2024

While numerous cardiovascular drug delivery devices and drug eluting stents are accessible for treating these conditions, treatment options for AF, including the anti-arrhythmic drugs, frequently prove ineffective.

Marketing 40

Marketing Protein Drug Delivery Development 40